Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oral Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis (VVC) in Subjects Who Have Failed Fluconazole Therapy

Next Previous
Trial Profile

Oral Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis (VVC) in Subjects Who Have Failed Fluconazole Therapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibrexafungerp (Primary)
  • Indications Vulvovaginal candidiasis
  • Focus Therapeutic Use
  • Acronyms VANQUISH
  • Sponsors SCYNEXIS

Most Recent Events

  • 28 Mar 2024 According to a SCYNEXIS media release, final study reports from FURI, CARES, SCYNERGIA, NATURE, and VANQUISH studies are anticipated to be delivered to GSK in the mid half of 2024, which would trigger a $10 million development milestone payment to SCYNEXIS.
  • 13 Nov 2023 According to Scynexis media release , the U.S. Food and Drug Administration (FDA) approved the first representative of this antifungal class BREXAFEMME (ibrexafungerp tablets) in June 2021, for its first indication in vulvovaginal candidiasis (VVC), followed by a second indication in November 2022, for reduction in the incidence of recurrent VVC.
  • 13 Nov 2023 According to Scynexis media release, status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top